157 related articles for article (PubMed ID: 32868574)
1. The Usefulness of Anti-acetylcholine Receptor Binding Antibody Testing in Diagnosing Ocular Myasthenia Gravis.
Chung IY; Sheth SJ; Wells KK; Campbell TG
J Neuroophthalmol; 2021 Dec; 41(4):e627-e630. PubMed ID: 32868574
[TBL] [Abstract][Full Text] [Related]
2. Clinical Utility of Acetylcholine Receptor Antibody Testing in Ocular Myasthenia Gravis.
Peeler CE; De Lott LB; Nagia L; Lemos J; Eggenberger ER; Cornblath WT
JAMA Neurol; 2015 Oct; 72(10):1170-4. PubMed ID: 26258604
[TBL] [Abstract][Full Text] [Related]
3. Ophthalmologic clinical features of ocular myasthenia gravis.
Kim DH; Roh HC; Oh SY
Medicine (Baltimore); 2023 Jan; 102(2):e31972. PubMed ID: 36637960
[TBL] [Abstract][Full Text] [Related]
4. Presence and pathogenic relevance of antibodies to clustered acetylcholine receptor in ocular and generalized myasthenia gravis.
Jacob S; Viegas S; Leite MI; Webster R; Cossins J; Kennett R; Hilton-Jones D; Morgan BP; Vincent A
Arch Neurol; 2012 Aug; 69(8):994-1001. PubMed ID: 22689047
[TBL] [Abstract][Full Text] [Related]
5. Autoantibodies in Japanese patients with ocular myasthenia gravis.
Nagaishi A; Narita T; Woodhall M; Jacobson L; Waters P; Irani SR; Vincent A; Matsuo H
Muscle Nerve; 2021 Feb; 63(2):262-267. PubMed ID: 33094484
[TBL] [Abstract][Full Text] [Related]
6. Ocular myasthenia gravis in an academic neuro-ophthalmology clinic: clinical features and therapeutic response.
Mittal MK; Barohn RJ; Pasnoor M; McVey A; Herbelin L; Whittaker T; Dimachkie M
J Clin Neuromuscul Dis; 2011 Sep; 13(1):46-52. PubMed ID: 22361625
[TBL] [Abstract][Full Text] [Related]
7. Adult Ocular Myasthenia Gravis Conversion: A Single-Center Retrospective Analysis in China.
Feng X; Huan X; Yan C; Song J; Lu J; Zhou L; Wu H; Qiao K; Lu J; Xi J; Luo S; Zhao C
Eur Neurol; 2020; 83(2):182-188. PubMed ID: 32526733
[TBL] [Abstract][Full Text] [Related]
8. Diagnostic yields and clinical features of ocular myasthenia gravis.
Kim H; Oh SY
Medicine (Baltimore); 2021 Jun; 100(25):e26457. PubMed ID: 34160444
[TBL] [Abstract][Full Text] [Related]
9. Antibody profile may predict outcome in ocular myasthenia gravis.
Galassi G; Mazzoli M; Ariatti A; Kaleci S; Valzania F; Nichelli PF
Acta Neurol Belg; 2018 Sep; 118(3):435-443. PubMed ID: 29858757
[TBL] [Abstract][Full Text] [Related]
10. Eye muscle antibodies in patients with ocular myasthenia gravis: possible mechanism for eye muscle inflammation in acetylcholine-receptor antibody-negative patients.
Gunji K; Skolnick C; Bednarczuk T; Benes S; Ackrell BA; Cochran B; Kennerdell JS; Wall JR
Clin Immunol Immunopathol; 1998 Jun; 87(3):276-81. PubMed ID: 9646837
[TBL] [Abstract][Full Text] [Related]
11. Factors Affecting Generalization of Ocular Myasthenia Gravis in Patients With Positive Acetylcholine Receptor Antibody.
Apinyawasisuk S; Chongpison Y; Thitisaksakul C; Jariyakosol S
Am J Ophthalmol; 2020 Jan; 209():10-17. PubMed ID: 31562855
[TBL] [Abstract][Full Text] [Related]
12. Acetylcholine receptor antibody positivity rate in ocular myasthenia gravis: a matter of age?
Monte G; Spagni G; Damato V; Iorio R; Marino M; Evoli A
J Neurol; 2021 May; 268(5):1803-1807. PubMed ID: 33387011
[TBL] [Abstract][Full Text] [Related]
13. Development of generalized disease at 2 years in patients with ocular myasthenia gravis.
Kupersmith MJ; Latkany R; Homel P
Arch Neurol; 2003 Feb; 60(2):243-8. PubMed ID: 12580710
[TBL] [Abstract][Full Text] [Related]
14. Diagnostic accuracy and clinical utility of bed side tests versus laboratory tests in the diagnosis of ocular myasthenia.
Sivakumar P; Tagare S; Kumar M
Indian J Ophthalmol; 2022 Apr; 70(4):1331-1337. PubMed ID: 35326049
[TBL] [Abstract][Full Text] [Related]
15. Factors affecting outcome in ocular myasthenia gravis.
Mazzoli M; Ariatti A; Valzania F; Kaleci S; Tondelli M; Nichelli PF; Galassi G
Int J Neurosci; 2018 Jan; 128(1):15-24. PubMed ID: 28625092
[TBL] [Abstract][Full Text] [Related]
16. Clinical Characteristics Associated With Secondary Generalization in Patients With Ocular Myasthenia Gravis: A Systematic Review and Meta-analysis.
Fang CEH; Bokre D; Wong SH
Neurology; 2023 Oct; 101(16):e1594-e1605. PubMed ID: 37643888
[TBL] [Abstract][Full Text] [Related]
17. Ocular motor dysfunction and ptosis in ocular myasthenia gravis: effects of treatment.
Kupersmith MJ; Ying G
Br J Ophthalmol; 2005 Oct; 89(10):1330-4. PubMed ID: 16170126
[TBL] [Abstract][Full Text] [Related]
18. Prognostic predictors of remission in ocular myasthenia gravis.
Çelebisoy N; Orujov A; Balayeva F; Özdemir HN; Ak AK; Gökçay F
Acta Neurol Belg; 2023 Oct; 123(5):1927-1932. PubMed ID: 36474006
[TBL] [Abstract][Full Text] [Related]
19. A retrospective study of acetylcholine receptor antibody positive ocular myasthenia in the West of Scotland.
Farrugia ME; Cleary M; Carmichael C
J Neurol Sci; 2017 Nov; 382():84-86. PubMed ID: 29111026
[TBL] [Abstract][Full Text] [Related]
20. Significance of Acetylcholine Receptor Antibody Titers in Acetylcholine Receptor Antibody-Positive Ocular Myasthenia Gravis: Generalization and Presence of Thyroid Autoimmune Antibodies and Thymoma.
Supawongwattana M; Vanikieti K; Jindahra P; Padungkiatsagul T
Clin Ophthalmol; 2023; 17():649-656. PubMed ID: 36875532
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
